PMID- 30172013
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200219
IS  - 1873-2763 (Electronic)
IS  - 1873-2763 (Linking)
VI  - 120
DP  - 2019 Mar
TI  - Long term time trends in use of medications associated with risk of developing 
      osteoporosis: Nationwide data for Denmark from 1999 to 2016.
PG  - 94-100
LID - S8756-3282(18)30324-7 [pii]
LID - 10.1016/j.bone.2018.08.019 [doi]
AB  - PURPOSE: To evaluate the development in the use of medications associated with an 
      increased risk of developing osteoporosis over the time period from 1999 to 2016. 
      METHODS: We extracted data on total sale, sales rate and usage rate for the 
      medications of interest from www.medstat.dk, which is an online, open-source 
      database reporting the monthly sale of both over-the-counter and 
      prescription-based medications in Denmark. The dataset covers both the primary 
      and secondary health sectors. RESULTS: Most medications exhibited an increasing 
      use from 1999 to 2016, though some had stable (e.g. glucocorticoids) or declining 
      use. Notably, some medications showed widespread and increasing use, including 
      proton pump inhibitors (PPI), selective serotonine reuptake inhibitors (SSRI) and 
      venlafaxine. For PPI, sales rates increased by 461% from 1999 to 2016, with 9% of 
      men and 11.4% of women filling at least one prescription in 2016. The use of SSRI 
      and venlafaxine increased by 114% and 613%, respectively. This was more 
      pronounced in women and for SSRI also in the elderly (80+ years). The sale of 
      aromatase inhibitors was moderate (1-10 DDD per 1000 capita per day) in 2016, yet 
      grew by 2400% from 1999, almost exclusively in women aged 80 years or older. 
      CONCLUSION: We found a trend of increasing use from 1999 to 2016 of most 
      medications with a potential for causing osteoporosis, often most pronounced in 
      fracture risk groups (postmenopausal women and/or in the elderly). This may play 
      a clinically relevant role in both current and future causality of osteoporosis.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Skjodt, M K
AU  - Skjodt MK
AD  - Department of Medicine, Hospital of Holbaek, Region Zealand, Smedelundsgade 60, 
      4300 Holbaek, Denmark. Electronic address: michael.skjoedt@gmail.com.
FAU - Ostadahmadli, Y
AU  - Ostadahmadli Y
AD  - Department of Medicine, Hospital of Holbaek, Region Zealand, Smedelundsgade 60, 
      4300 Holbaek, Denmark.
FAU - Abrahamsen, B
AU  - Abrahamsen B
AD  - Department of Medicine, Hospital of Holbaek, Region Zealand, Smedelundsgade 60, 
      4300 Holbaek, Denmark; Odense Patient Data Explorative Network, Institute of 
      Clinical Research, University of Southern Denmark, Winslowparken 9, 5000 Odense 
      C, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20180830
PL  - United States
TA  - Bone
JT  - Bone
JID - 8504048
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Denmark/epidemiology
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoporosis/*epidemiology/*etiology
MH  - Risk Factors
MH  - Time Factors
OTO - NOTNLM
OT  - Glucocorticoids
OT  - Osteoporosis
OT  - Pharmacoepidemiology
OT  - Proton pump inhibitors
OT  - Public health
OT  - Selective serotonin reuptake inhibitors
EDAT- 2018/09/02 06:00
MHDA- 2020/02/20 06:00
CRDT- 2018/09/02 06:00
PHST- 2018/04/19 00:00 [received]
PHST- 2018/08/18 00:00 [revised]
PHST- 2018/08/29 00:00 [accepted]
PHST- 2018/09/02 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
PHST- 2018/09/02 06:00 [entrez]
AID - S8756-3282(18)30324-7 [pii]
AID - 10.1016/j.bone.2018.08.019 [doi]
PST - ppublish
SO  - Bone. 2019 Mar;120:94-100. doi: 10.1016/j.bone.2018.08.019. Epub 2018 Aug 30.